Raging Capital Hopes To Profit On Biotech Crash – ValueWalk Premium

Raging Capital Hopes To Profit On Biotech Crash

Activist hedge fund, Raging Capital Management, managed by William C Martin gained 0.8% net of all fees and expenses during the second quarter. Year to date the fund is up 1.8% net, according to a letter to investors reviewed by ValueWalk.

Since inception (April 2006) the Raging Capital Master Fund -- Series B has returned 620.6%, a compound annual growth rate of 23.8%, compared to the S&P 500's total return of 94%, a CAGR of 7.4%.

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

0